About Vakzine Projekt Management
VPM offers tailor-made consultancy and services based on in-depth experience in development of biopharmaceutical candidates. As a client, you will benefit from the experience of our team in translational project management. This enables you to bring your development projects into clinical trials faster, more cost-effectively and with a higher probability of success.
The company was established in 2002. Within the last decade, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. VPM brought these products for its customers in the pharmaceutical industry, academic research and small biotechnology companies, from preclinical phase through clinical phases I-III.More about us
News & Press
"MHH testet Corona-Impfstoff – besser als Biontech & Co.?" Read more!
Vakzine Projekt Management GmbH (VPM) announces that the first participant has been enrolled in a large phase III trial to assess the efficacy and safety of the novel TB vaccine – VPM1002 - in comparison with BCG in healthy newborn infants. Read more!
Following the successful completion of phase II part of the Tdap study (tetanus, diphtheria and pertussis) Tadeus, phase III part will commence this week, which will include adults, adolescents and children to test the safety and immunogenicity of this vaccine. Read more!